Skip to main content
. 2020 Jul 28;4(14):3382–3390. doi: 10.1182/bloodadvances.2020001551

Table 3.

Univariable and multivariable analysis

EFS OS
Univariable HR P Multivariable HR P Univariable HR P Multivariable HR P
Age >60 y 1.5 (0.8-2.9) .2 1.7 (0.8-3.6) .2
ABC subtype 1.3 (0.7-2.4) .5 1.4 (0.7-2.9) .4
Ki67 ≥90% 0.9 (0.5-1.8) .8 1.2 (0.6-2.4) .6
ECOG score >1 4.4 (2.4-8.3) <.001 2.2 (1.1-4.5) .032 6.1 (3.0-12.5) <.001 3.3 (1.3-7.9) .006
Stages III-IV 6.6 (2.0-21) <.001 1.9 (0.5-7.3) .3 4.8 (1.5-15.8) .001 1.3 (0.3-5.5) .7
B symptoms 2.4 (1.2-4.9) .026 1.7 (0.7-3.7) .2 3.0 (1.4-6.4) .008 1.9 (0.8-4.5) .2
Bulk (≥10 cm) 0.7 (0.3-1.5) .3 0.5 (0.2-1.2) .11
Elevated LDH 5.9 (2.3-15) <.001 2.5 (0.85-7.3) .08 4.3 (1.6-11.1) <.001 1.6 (0.5-5.2) .4
Extranodal sites >1 7.6 (2.3-25) <.001 3.0 (0.8-11) .2 8.1 (1.9-34.7) .001 3.7 (0.77-17.9) .11
FISH
 WT Ref .063 .2 Ref .4 .5
 EC 0.8 (0.3-1.8) 0.8 (0.4-2.0) 0.9 (0.4-2.3) 1.1 (0.4-2.8)
 DHL 1.8 (0.9-3.8) 1.7 (0.8-3.9) 1.5 (0.7-3.6) 1.8 (0.7-4.5)

Data are HR (95% CI). Bold indicates statistically significant results.

ABC, activated B cell; ECOG, Eastern cooperative oncology group; HR, hazard ratio; Ref, reference.

HHS Vulnerability Disclosure